The Form 4 filing, an SEC report of insider stock activity, was filed on November 18, 2026. It lists November 17, 2026, as the sale date. Anni Lotte Kirstine Sonderbjerg Pedersen is executive vice president and chief administrative officer at Ascendis Pharma A/S (ASND).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 20,000 |
| Price | $263.89 |
| Total Transaction Value | $5,277,720.00 |
| Insider | |
| Ticker Symbol | ASND |
| Company | Ascendis Pharma A/S |
| Insider Name | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG |
| Insider Title | EVP & Chief Admin Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 19,460 |
| Position Size Change | 50.68% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale under transaction code S, with an indicated link to an exercise or conversion. An exercise uses a right to get shares. A conversion exchanges another type of investment for shares.
What was the average price of the transaction?
The average sale price was $263.886 per share, or $263.89 when rounded to cents.
How did this transaction affect the insider's holdings?
The sale involved 20,000 shares, with 19,460 shares reported as owned afterward. The shares sold represented 50.68% of the reported shares held before the sale.
What's the total transaction value?
The total transaction value was $5,277,720.00. This amount covers one reported sale.
Are there any special circumstances around this transaction?
Yes. The sale is marked as linked to a code M exercise or conversion through matching share counts in the same filing. This suggests a connection between shares received and shares sold.
Details of the related code M entry and the filing's footnotes are unavailable here. The match does not confirm the dates, share types, accounts, or whether the exact shares received were sold. It also does not show why the sale happened, whether it was required, or how any exercise was paid for.
For research purposes only; not investment advice.